Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with interstitial lung disease that was associated with sorafenib therapy for the treatment of advanced hepatocellular carcinoma. A 74-year-old man with hepatitis-C-virus-related hepatocellular carcinoma was treated with sorafenib. After 8 days of sorafenib administration, he received radiation therapy for an intrahepatic tumor located in segment eight. On the 24th day of sorafenib treatment, the patient developed acute interstitial pneumonitis that rapidly improved after the discontinuation of sorafenib and treatment with high-dose steroids. This case alerts physicians to the possibility of sorafenib-induced interstitial lung disease.
Abstract
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with interstitial lung disease that was associated with sorafenib therapy for the treatment of advanced hepatocellular carcinoma. A 74-year-old man with hepatitis-C-virus-related hepatocellular carcinoma was treated with sorafenib. After 8 days of sorafenib administration, he received radiation therapy for an intrahepatic tumor located in segment eight. On the 24th day of sorafenib treatment, the patient developed acute interstitial pneumonitis that rapidly improved after the discontinuation of sorafenib and treatment with high-dose steroids. This case alerts physicians to the possibility of sorafenib-induced interstitial lung disease.
참고문헌 (19)
- Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Escudier B, "Sorafenib in advanced clear-cell renal-cell carcinoma", N Engl J Med, 356, pp.125~134 (2007)
- Abou-Alfa GK, "Phase II study of sorafenib in patients with advanced hepatocellular carcinoma", J Clin Oncol, 24, pp.4293~4300 (2006)
- Gross NJ, "Pulmonary effects of radiation therapy", Ann Intern Med, 86, pp.81~92 (1977)
- Roswit B, "Severe radiation injuries of the lung", AJR Am J Roentgenol, 129, pp.127~136 (1977)
- Jennnings FL, "Development of radiation pneumonitis. Time and dose factors", Arch Pathol, 74, pp.351~360 (1962)
- Libshitz HI, "Complications of radiation therapy: the thorax", Semin Roentgenol, 9, pp.41~49 (1974)
- Movsas B, "Pulmonary radiation injury", Chest, 111, pp.1061~1076 (1997)
- Roach M 3rd, "Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors", J Clin Oncol, 13, pp.2606~2612 (1995)
- Ikezoe J, "Acute radiation-induced pulmonary injury: computed tomography evaluation", Semin Ultrasound CT MR, 11, pp.409~416 (1990)
- Gotoh A, "Lung injury associated with bortezomib therapy in relapsed", refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology, 2006, pp.84, 406~412
- Cohen MH, "FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets", Oncologist, 8, pp.303~306 (2003)
- Gemma A, "Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents", J Nippon Med Sch, 76, pp.4~8 (2009)
- Maitre B, "Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury", Eur Respir J, 18, pp.100~106 (2001)
- Hanaoka M, "Vascular endothelial growth factor in patients with high-altitude pulmonary edema", J Appl Physiol, 94, pp.1836~1840 (2003)
- Abadie Y, "Decreased VEGF concentration in lung tissue and vascular injury during ARDS", Eur Respir J, 25, pp.139~146 (2005)
- Meyer KC, "Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease", J Lab Clin Med, 135, pp.332~338 (2000)
- Vasakova M, "Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases", Scand J Immunol, 69, pp.268~274 (2009)